Shots:

• The company reported new post hoc data from the P- III ASCLEPIOS trials assessing Kesimpta (ofatumumab) vs teriflunomide in a subgroup of newly diagnosed- treatment-naïve patients with RMS
• The results showed a 60% reduction in the risk of disability progression independent of relapse activity @3 and 6 mos.- thus supporting Kesimpta as a 1L treatment option for adults with RMS. The data is presented at AAN2021
• Emerging OLE study data from the ALITHIOS trial showed that Kesimpta precisely delivered through SC administration- mean serum IgM/IgG levels remained within the reference ranges over a 3yrs. period to Dec 2020

  Ref: Novartis | Image: Novartis